益气和胃胶囊治疗慢性非萎缩性胃炎的疗效及机制

Effect and mechanism of Yiqihewei Capsules in the treatment of chronic nonatrophic gastritis

目的探讨益气和胃胶囊在慢性非萎缩性胃炎(CNAG)中的临床应用价值。方法随机选取就诊的112例患者作为研究对象,用随机数字表法分组,每组56例。对照组患者口服奥美拉唑,观察组患者联合使用益气和胃胶囊,用药4周。观察2组用药前和用药4周后的中医症候积分(胃脘痞胀、胃脘疼痛、食欲不振和嗳气)、炎症指标[白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)、C反应蛋白(CPR)和肿瘤坏死细胞因子-α(TNF-α)]、胃肠激素[胃泌素(GAS)、胃动素(MTL)、生长抑素(SS)和表皮生长因子(EGF)]以及胃黏膜组织生化指标[热休克蛋白70(HSP70)和β-连环蛋白(β-Catenin)]变化情况,评估临床治疗效果及用药安全性。结果2组患者用药4周后的胃脘痞胀、胃脘疼痛、食欲不振、嗳气评分及血清IL-6、IL-1β、CRP和TNF-α指标明显降低(P<0.05),且观察组以上指标较对照组降低更明显(P<0.05)。2组患者用药4周后的GAS指标和β-Catenin阳性细胞面密度值降低,MTL、EGF、SS指标和HSP70阳性细胞面密度值提高(P<0.05),观察组用药4周后的血清GAS指标和β-Catenin阳性细胞面密度值与对照组比较明显降低,MTL、EGF、SS指标和HSP70阳性细胞面密度值与对照组比较明显提高(P<0.05)。观察组治疗总有效率(94.64%)明显高于对照组(85.71%),P<0.05。观察组不良反应发生率(10.71%)与对照组(8.93%)比较,差异无统计学意义(P>0.05)。结论益气和胃胶囊治疗CNAG能显著缓解症状,减轻机体炎症反应,保护胃黏膜组织,疗效显著,安全可靠。

Objective To explore the clinical application value of Yiqihewei Capsules in chronic non-atrophic gastritis(CNAG).Methods 112 patients were randomly selected as the research objects,and were divided into groups by using a random number table method,with 56 cases in each group.The patients in the control group took omeprazole orally,and the patients in the observation group used Yiqihewei Capsules for 4 weeks.The traditional Chinese medicine(TCM)syndrome scores(gastric bloating,gastric pain,loss of appetite and belching)before and after 4 weeks of medication,the inflammation indicators[interleukin-6(IL-6),interleukin-1β(IL-1β),C-reactive protein(CPR)and tumor necrosis factor-α(TNF-α)],gastrointestinal hormones[gastrin(GAS),motilin(MTL),somatostatin(SS)and epidermal growth factor(EGF)],gastric mucosal tissue biochemical indicators[heat shock protein 70(HSP70)and β-Catenin]changes were observed and recorded,and the clinical treatment effect and medication safety were evaluated.Results After 4 weeks of medication,the gastric bloating,gastric pain,loss of appetite and belching scores,and serum IL-6,IL-1β,CRP and TNF-α indicators of both groups were significantly reduced(P<0.05),and the observation group were better than the control group(P<0.05).The GAS index and β-Catenin positive cell area density values of the 2 groups of patients after 4 weeks of medication decreased,and the MTL,EGF,SS indicators and HSP70 positive cell area density values increased(P<0.05).The area density of β-Catenin positive cells was significantly lower than that of the control group,and the area density values of MTL,EGF,SS and HSP70 positive cells were significantly higher than those of the control group(P<0.05).The total effective rate of treatment in the observation group was 94.64%,which was significantly higher than 85.71% in the control group(P<0.05).The adverse reaction rate in the observation group was 10.71%,compared with 8.93% in the control group,there was no significant difference(P>0.05).Conclusion The treatment of CNAG with Yiqihewei Capsules can significantly relieve symptoms,reduce the body's inflammatory response,and protect gastric mucosa.It has outstanding efficacy,safety and reliability.